Comparison of the effect of beta-alanyl-L-histidinato zinc and its zinc-chelating ligand on bone metabolism in tissue culture.
The present investigation was undertaken to compare the effects of beta-alanyl-L-histidinato zinc (AHZ) and its zinc-chelating ligands on bone metabolism in tissue culture. Calvaria were removed from 3-week-old male rats and cultured for up to 72 h in Dulbecco's modified eagle medium containing zinc sulfate, AHZ, di(N-acetyl-beta-alanyl-L-histidinato)zinc (AAHZ), and di(histidino)zinc (HZ). The bone calcium content and alkaline phosphatase activity were significantly increased in the presence of AHZ or AAHZ (10(-8)-10(-5) M). Those increases were seen at 10(-7) to 10(-5) M zinc sulfate and HZ. The bone deoxyribonucleic acid (DNA) content was significantly increased by AHZ or AAHZ with 10(-7) to 10(-5) M, while 10(-7) M zinc sulfate and HZ had no effect. Thus, AHZ and AAHZ had more potent effect than that of zinc sulfate and HZ. The effect of AHZ, AAHZ and HZ (10(-5) M) increasing bone alkaline phosphatase activity was abolished by the presence of 10(-4) M dipicolinate, a chelator of zinc. Moreover, the effect of these zinc compounds on bone metabolic indices was not seen in the presence of 10(-6) M cycloheximide. The present results suggest that the effect of AHZ and AAHZ on bone metabolism is more potent than that of zinc sulfate and HZ.
Yamaguchi
M
M
Laboratory of Metabolism and Endocrinology, Graduate School of Nutritional Sciences, University of Shizuoka, Japan.
Kishi
S
S
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002336:Carnosine / Q000031:analogs & derivatives*; D002614:Chelating Agents / Q000494:pharmacology; D046508:Culture Techniques; D003513:Cycloheximide / Q000494:pharmacology; D004247:DNA / Q000378:metabolism; D004151:Dipeptides / Q000494:pharmacology*; D006639:Histidine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D009942:Organometallic Compounds / Q000494:pharmacology*; D051381:Rats; D015032:Zinc / Q000494:pharmacology*; D017967:Zinc Compounds
D002614:Chelating Agents; D004151:Dipeptides; D009942:Organometallic Compounds; D017967:Zinc Compounds; C089030:di(N-acetylalanyl-histidinato)zinc; C089031:di(histidino)zinc; C061957:polaprezinc; D006639:Histidine; D002336:Carnosine; D004247:DNA; D003513:Cycloheximide; D000469:Alkaline Phosphatase; D015032:Zinc; D002118:Calcium